Exagen Diagnostics Names Thomas Williams, M.D., Special Advisor for Molecular Pathology

Mar 21, 2005, 00:00 ET from Exagen Diagnostics, Inc.

    ALBUQUERQUE, N.M., March 21 /PRNewswire/ -- Exagen Diagnostics, Inc., an
 emerging leader in the rapid identification and productization of practical,
 genomic markers for prognostic testing, today announced that Thomas Williams,
 M.D., joined the company as special advisor for molecular pathology. Dr.
 Williams will provide Exagen executives with scientific and market-based
 counsel on unmet needs in pathology.
     Dr. Williams is vice chairman, department of pathology, at the University
 of New Mexico School of Medicine. In addition, he serves as director of the
 Genetics and Cytometry Division at TriCore Reference Laboratories, a regional
 medical laboratory affiliated with the University of New Mexico Health
 Sciences Center and Presbyterian Healthcare Services, where he is responsible
 for medical direction of the molecular diagnostics laboratory. Dr. Williams
 has acted as principal investigator in several cancer-related Human Leukocyte
 Antigen (HLA)-focused research studies, and has a special interest in gene
 expression work related to hepatitis C discovery and study.
     Exagen's first prognostic reagents for breast cancer use small sets of
 genes in combination to detect DNA changes, making them more accurate, more
 practical and more efficient than any other prognostic test currently
 available to guide treatment of breast cancer patients. The company's next set
 of prognostic reagents is being developed to identify those patients who may
 benefit from standard treatment for hepatitis C and to identify patients at
 risk for development of liver cancer.
     About Exagen Diagnostics, Inc.
     As an emerging leader in prognostic testing, Exagen Diagnostics is
 uniquely able to define small sets of genomic markers that are more accurate
 than other approaches, whether for breast cancer, infectious disease or other
 indications. Exagen's proprietary discovery and implementation technologies
 enable the rapid identification and productization of optimized DNA or RNA
 genomic marker sets for prognostic or predictive testing, either for
 diagnostic testing by reference laboratories or for pharmaceutical R&D
 purposes. For more information, visit www.exagendiagnostics.com.

SOURCE Exagen Diagnostics, Inc.